Adult Brain Tumors
A seven-year study suggests that there may be a new way to treat Glioblastoma Multiforme, one of the most common and deadly forms of brain cancer in adults (GBM).
Scientists from the University of Surrey reveal that a short chain of amino acids (the HTL-001 peptide) successfully targets and inhibits the function of a family of genes responsible for the formation of GBM – Hox genes – in a peer-reviewed study published in BMC Cancer. The research was carried out using cell and animal models.
The HTL-001 peptide utilized in the study has passed safety tests and is ready for clinical trials. GBM and other malignancies are currently being investigated for these trials.
Hardev Pandha, research leader and University of Surrey Professor of Medical Oncology, said: ” “Glioblastoma Multiforme patients have a five-year survival rate of 5%, which has not improved in decades. While we are still early in the process, our seven-year initiative provides a ray of hope for discovering a cure for Hox gene dysregulation, which is linked to the progression of GBM and other cancers and has eluded researchers for years.”
